Incyte Corporation
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Incyte Corporation's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Debt due within a year is covered 138.4 times by its yearly operating cash. Higher than 98% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 9.7 times. Higher than 95% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 3 of the last 3 years; profit grew in 2 of 3. Steadier than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$117Over the last 3 years, every $100 of reported profit came with $117 of operating cash.
Lower than 73% of Healthcare companies in United States.
Self-Funding Ratio
9.7×Over the last 3 years its own operating cash covered its investment spending (capex) 9.7 times.
Higher than 95% of Healthcare companies in United States.
Cash Locked Ratio
$18For every $100 of sales, $18 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $12 tied up three years earlier.
Less money tied up than 63% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$54Sales grew 51% in 3 years; of every extra $100 of sales, $54 became extra profit.
Higher than 72% of Healthcare companies in United States.
Asset Productivity Ratio
+51% / +19%In 3 years sales changed by +51% while total assets changed by +19%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
138.4×Debt due within a year is covered 138.4 times by its yearly operating cash.
Higher than 98% of Healthcare companies in United States.
Cash Cushion Ratio
+15%Cash, after subtracting all debt, equals 15% of its market value (net cash).
Higher than 57% of Healthcare companies in United States.
Tangible Assets Ratio
96%Of every $100 the company owns, $96 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 77% of Healthcare companies in United States.
Tangible Net Worth Ratio
95%Of every $100 of net worth, $95 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 81% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Incyte Corporation owes $0.19 for every $1 it owns. Net profit rose 3845% in the year to Dec 2025, and grew 56% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
14.9Investors pay $14.9 for every $1 of Incyte Corporation's yearly profit, lower than 75% of Healthcare companies in United States.
P/B ratio
3.74The share price is 3.74 times Incyte Corporation's book value per share, higher than 63% of Healthcare companies in United States.
Market cap
$23.7 BThe total market value of all of Incyte Corporation's shares at today's price (share price × number of shares), larger than 94% of Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$6.3 BWhat Incyte Corporation would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$31.30Net worth divided by the number of shares. The share price of $116.93 is 3.7 times this, which is the P/B above.
Return on equity (ROE)
30.7%Incyte Corporation earned 30.7% on its shareholders' money over the last year, higher than 94% of Healthcare companies in United States.
Owes vs Owns
0.19×Incyte Corporation owes $0.19 for every $1 it owns (low), lower than 73% of Healthcare companies in United States.
Dividend yield
NoneIncyte Corporation does not currently pay a dividend.
Revenue growth
+21%Revenue rose 21% in the year to Dec 2025, and grew 15% a year on average over 3 years.
Profit growth
+3845%Net profit rose 3845% in the year to Dec 2025, and grew 56% a year on average over 3 years.
Profit margin
25.0%Incyte Corporation keeps $25 of every $100 of revenue as net profit.
Cash quality
1.10×Cash from Incyte Corporation's business was 1.10× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
553.0×Incyte Corporation's operating profit covered its interest costs 553.0 times in the year to Dec 2025.
Cash vs debt
Net cashIncyte Corporation held $3.5 B more cash than debt (net cash) at Dec 2025.
Questions
What is Incyte Corporation's P/E ratio?
Investors pay $14.9 for every $1 of Incyte Corporation's yearly profit, lower than 75% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Incyte Corporation: $23.7 B ÷ $6.3 B (30 Jun 2026) = 3.7.
What is Incyte Corporation's return on equity?
Incyte Corporation earned 30.7% on its shareholders' money over the last year, higher than 94% of Healthcare companies in United States.
How much does Incyte Corporation owe compared with what it owns?
Incyte Corporation owes $0.19 for every $1 it owns (low), lower than 73% of Healthcare companies in United States.
Does Incyte Corporation pay a dividend?
No. Incyte Corporation does not currently pay a dividend.
Is Incyte Corporation's revenue growing?
Revenue rose 21% in the year to Dec 2025, and grew 15% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.